Drug
Heplisav B
Heplisav B: highest development phase Phase 3, developed by Dynavax Technologies, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Dynavax Technologies, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| HEPLISAV-B NCT04193189 | Phase 3 | HIV Infection |
| HEPLISAV-B NCT00985426 | Phase 3 | Chronic Kidney Disease |
| HEPLISAV-B® NCT03934736 | Phase 1 | End Stage Renal Disease on Hemodialysis (Diagnosis) |
Latest
No recent events.
Follow Heplisav B on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.